Ankur Rughani
Pediatric Endocrinology · Oklahoma City, OKNPI 1346628856
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,416 of the $20,380 with a category attached, or 60.9%. Sanofi-aventis U.S. LLC accounts for 60.5% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $14,260, more than ten times the $125 reported in 2019.
Across 228 payments — averaging $89.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$12K
- AstraZeneca$2K
- Kyowa Kirin, Inc.$1K
- Ascendis Pharma Endocrinology Inc$588
- Tandem Diabetes Care, Inc.$517
- Tolmar, Inc.$421
- plus $3K from 29 others
What the payments were for
- Consulting fees$1,98010%
- Speaking & faculty fees$12,41661%
- Food & beverage$5,89629%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 38 | $12,330 |
| AstraZeneca | 8 | $2,288 |
| Kyowa Kirin, Inc. | 7 | $1,369 |
| Ascendis Pharma Endocrinology Inc | 20 | $588 |
| Tandem Diabetes Care, Inc. | 17 | $517 |
| Tolmar, Inc. | 14 | $421 |
| AbbVie | 16 | $341 |
| BETA Bionics, Inc. | 8 | $320 |
| Xeris Pharmaceuticals, Inc. | 12 | $229 |
| Abbott | 12 | $217 |
| Biomarin Pharmaceutical Inc. | 7 | $170 |
| UCB, Inc. | 7 | $136 |
| Eisai Inc. | 7 | $132 |
| Dexcom, Inc. | 6 | $132 |
| Novo Nordisk | 5 | $125 |
| Eton Pharmaceuticals, Inc. | 3 | $121 |
| Insulet Corporation | 5 | $113 |
| Pfizer | 4 | $99 |
| Neurocrine Biosciences, Inc. | 3 | $82 |
| Rhythm Pharmaceuticals, Inc. | 3 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| Regeneron Healthcare Solutions, Inc. | 3 | $74 |
| Tolmar Pharmaceuticals, Inc. | 3 | $66 |
| Mannkind Corporation | 2 | $62 |
| Lilly USA, LLC | 3 | $53 |
| Neurelis, Inc. | 2 | $37 |
| Aquestive Therapeutics, Inc. | 2 | $32 |
| Sequel Med Tech, LLC | 1 | $25 |
| Soleno Therapeutics, Inc. | 1 | $24 |
| Endo USA, Inc. | 1 | $24 |
| PTC Therapeutics, Inc. | 1 | $24 |
| Medtronic | 1 | $23 |
| Sanofi | 1 | $20 |
| IBSA Pharma Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$9,950
- CRYSVITA$1,169
- Strensiq$1,025
- iLet Bionic Pancreas$774
- iLet Insulin Infusion Kit Inset$258
- iLet Insulin Infusion Kit Contact Detach$258
- SKYTROFA$232
- FENSOLVI$131
- t:slim X2 Insulin Pump with Control-IQ$115
How this compares
Too few pediatric endocrinology providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Other pediatric endocrinology in Oklahoma City
- Steven ChernausekOklahoma City$41K
- Kenneth CopelandOklahoma City$15K
- Rebecca SchaubOklahoma City$3K
- David SparlingOklahoma City$1K
- Paul DasariOklahoma City$1K
- Minu GeorgeOklahoma City$511
- Maha YousifOklahoma City$309
- Jonathan MeyerOklahoma City$216
- Piers BlackettOklahoma City$124
- Shelly MercerTulsa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.